Randomized phase 2/3 trial of transcatheter arterial chemoembolization (TACE) plus sunitinib or placebo in patients with hepatocellular carcinoma (HCC) (PRODIGE 16/SATURNE study): Results of the Phase II part

被引：2
|
作者：
Hebbar, M. [1 ]
Heurgue-Berlot, A. [2 ]
Boige, V. [3 ]
Le Malicot, K. [4 ]
Bernard-Chabert, B. [2 ]
Marcus, C. [5 ]
Dharancy, S. [6 ]
Sergent, G. [7 ]
Perarnau, J. M. [8 ]
Ehrhard, F. [9 ]
Ollivier-Hourmand, I. [10 ]
Vergniol, J. [11 ]
Michel, P. [12 ]
Edeline, J. [13 ]
Rinaldi, Y. [14 ]
Seitz, J. F. [15 ]
Lepage, C. [16 ]
De Baere, T. [17 ]
机构：
[1] Ctr Hosp Huriez, Med Oncol, Lille, France
[2] Univ Hosp, Hepatol, Reims, France
[3] Gustave Roussy, Digest Oncol, Villejuif, France
[4] Federat Francophone Cancerol Digest, Biostat, Dijon, France
[5] Univ Hosp, Radiol, Reims, France
[6] Ctr Hosp Huriez, Hepatol, Lille, France
[7] Ctr Hosp Huriez, Radiol, Lille, France
[8] Univ Hosp, Gastroenterol, Tours, France
[9] Univ Hosp, Gastroenterol, Reims, France
[10] Univ Hosp, Gastroenterol, Caen, France
[11] Univ Hosp, Gastroenterol, Pessac, France
[12] Univ Hosp, Gastroenterol, Rouen, France
[13] Anticanc Ctr, Oncol, Rennes, France
[14] Hop Ambroise Pare, Gastroenterol, Marseille, France
[15] La Timone Univ Hosp, Digest Oncol, Marseille, France
[16] Univ Hosp, Gastroenterol, Dijon, France
[17] Gustave Roussy, Radiol, Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31221-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2305
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [31] Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria
    Yamashita, T.
    Ueshima, K.
    Tsuchiya, K.
    Kato, N.
    Shimose, S.
    Numata, K.
    Kodama, Y.
    Ohkawa, K.
    Kuzuya, T.
    Ikeda, M.
    Kooka, Y.
    Aikata, H.
    Hiraoka, A.
    Moriguchi, M.
    Fujiwara, K.
    Suda, G.
    Mochida, S.
    Ogasawara, S.
    Yamamoto, K.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1484
  • [32] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Interim analysis of START: Study in asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial
    Chung, Young-Hwa
    Han, Guohong
    Yoon, Jung-Hwan
    Yang, Jijin
    Wang, Jianhua
    Shao, Guo-Liang
    Kim, Byung Ik
    Lee, Teng-Yu
    Chao, Yee
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (10) : 2448 - 2458
  • [34] Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial.
    Poon, Ronnie Tung Ping
    Chen, Li-Tzong
    Xue, Hong-Ling
    Tannir, Bayane
    Wang, Jia Hua
    Tanwandee, Tawesak
    Paik, Seung-Woon
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.
    Chan, Stephen Lam
    Yeo, Winnie
    Mo, Frankie
    Li, Leung
    Lee, Kit Fai
    Chan, Anthony W. H.
    Hui, Edwin Pun
    Lai, Paul B. S.
    Mok, Tony
    Chan, Anthony T. C.
    Yu, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Evaluation of transcatheter arterial chemoembolization (TACE) plus sorafenib in Chinese patients with unresectable hepatocellular carcinoma: A subgroup analysis of START trial.
    Han, Guohong
    Yang, Jijin
    Shao, Guoliang
    Teng, Gaojun
    Wang, Maoqiang
    Yang, Jianyong
    Liu, Zhaoyu
    Feng, Gansheng
    Yang, Renjie
    Lu, Ligong
    Chao, Yee
    Wang, Jianhua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] A randomized phase II study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) as a bridge to transplant in hepatocellular carcinoma (HCC).
    Nugent, Francis Warren
    Gunturu, Krishna
    Stuart, Keith E.
    Flacke, Sebastian
    Molgaard, Chris
    Hunter, Klaudia
    Qamar, Amir
    Iqbal, Shams
    Gordon, Frederick
    Galuski, Kari
    Hartnett, Erin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] Gemcitabine plus oxallplatin (GEMOX) in advanced hepatocellular carcinoma (HCC): results of a phase II study
    Mansourbakht, T.
    Boige, V.
    Louafi, S.
    Bonyhay, L.
    De Baere, T.
    Ducreux, M.
    Poynard, T.
    Taieb, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 215 - 215
12345